CEO Norman Schwartz noted that despite macroeconomic headwinds, the company is focusing on long-term opportunities in life science research and diagnostics markets. Schwartz emphasized Bio-Rad's ...
Bio-Path Holdings, Inc. has announced a positive outlook for 2025, building on advancements made in 2024 in their clinical development pipeline, which includes targeted nucleic acid drugs for cancer ...
INmune Bio is working with the FDA to define a path forward for the therapy based on these results. According to the company, its cash position stood at approximately $27.7 million as of September 30, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results